{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T19:00:34Z","timestamp":1775588434197,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,9,27]],"date-time":"2018-09-27T00:00:00Z","timestamp":1538006400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2018,9,27]],"date-time":"2018-09-27T00:00:00Z","timestamp":1538006400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000051","name":"National Human Genome Research Institute","doi-asserted-by":"publisher","award":["U01 HG007436-04"],"award-info":[{"award-number":["U01 HG007436-04"]}],"id":[{"id":"10.13039\/100000051","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","award":["U01 FD004979"],"award-info":[{"award-number":["U01 FD004979"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12885-018-4833-4","type":"journal-article","created":{"date-parts":[[2018,9,27]],"date-time":"2018-09-27T08:40:49Z","timestamp":1538037649000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Data mining of digitized health records in a resource-constrained setting reveals that timely immunophenotyping is associated with improved breast cancer outcomes"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3409-1815","authenticated-orcid":false,"given":"Arturo","family":"L\u00f3pez-Pineda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9790-1048","authenticated-orcid":false,"given":"Mario F","family":"Rodr\u00edguez-Moran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1206-6659","authenticated-orcid":false,"given":"Cleto","family":"\u00c1lvarez-Aguilar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8571-9537","authenticated-orcid":false,"given":"Sarah M","family":"Fuentes Valle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rom\u00e1n","family":"Acosta-Rosales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8099-2975","authenticated-orcid":false,"given":"Ami S","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shruti N","family":"Sheth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2884-4286","authenticated-orcid":false,"given":"Carlos D","family":"Bustamante","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,9,27]]},"reference":[{"key":"4833_CR1","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s10549-013-2620-0","volume":"140","author":"EH Lips","year":"2013","unstructured":"Lips EH, Mulder L, de Ronde JJ, IAM M, Koolen BB, LFA W, et al. Breast cancer subtyping by immunohistochemistry and histological grade outperforms breast cancer intrinsic subtypes in predicting neoadjuvant chemotherapy response. Breast Cancer Res Treat Springer US. 2013;140:63\u201371.","journal-title":"Breast Cancer Res Treat Springer US"},{"key":"4833_CR2","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1038\/modpathol.2013.97","volume":"26","author":"JR Won","year":"2013","unstructured":"Won JR, Gao D, Chow C, Cheng J, Lau SYH, Ellis MJ, et al. A survey of immunohistochemical biomarkers for basal-like breast cancer against a gene expression profile gold standard. Mod Pathol. 2013;26:1438\u201350.","journal-title":"Mod Pathol"},{"issue":"Suppl 2","key":"4833_CR3","doi-asserted-by":"publisher","first-page":"S83","DOI":"10.1016\/j.breast.2013.07.015","volume":"22","author":"M Abu-Khalf","year":"2013","unstructured":"Abu-Khalf M, Pusztai L. Influence of genomics on adjuvant treatments for pre-invasive and invasive breast cancer. Breast. 2013;22(Suppl 2):S83\u20137.","journal-title":"Breast"},{"key":"4833_CR4","unstructured":"Cardenas Sanchez J, Rocha JEB, Pi\u00f1a VB, S\u00e1nchez GC, Erazo Valle-Sol\u00eds AA, Balc\u00e1zar CHF, et al. Mexican Consensus on the Diagnosis and Treatment of Breast Cancer: Seventh Revision - Colima 2017. Gaceta Mexicana de Oncolog\u00eda. 2017;16:7\u201378."},{"key":"4833_CR5","first-page":"1","volume-title":"Diagn\u00f3stico y Tratamiento de la Patolog\u00eda Mamaria Benigna en Primer y Segundo Nivel de Atenci\u00f3n","author":"Secretaria de Salud de Mexico","year":"2009","unstructured":"Secretaria de Salud de Mexico. Diagn\u00f3stico y Tratamiento de la Patolog\u00eda Mamaria Benigna en Primer y Segundo Nivel de Atenci\u00f3n; 2009. p. 1\u201366."},{"key":"4833_CR6","first-page":"1","volume-title":"Prevenci\u00f3n, Tamizaje y Referencia Oportuna de Casos Sospechosos de C\u00e1ncer de Mama en el Primer Nivel de Anteci\u00f3n","author":"Secretaria de Salud de Mexico","year":"2011","unstructured":"Secretaria de Salud de Mexico. Prevenci\u00f3n, Tamizaje y Referencia Oportuna de Casos Sospechosos de C\u00e1ncer de Mama en el Primer Nivel de Anteci\u00f3n; 2011. p. 1\u201374."},{"key":"4833_CR7","first-page":"1","volume-title":"Diagn\u00f3stico y Tratamiento del C\u00e1ncer de Mama en Segundo y Tercer Nivel de Atenci\u00f3n","author":"Secretaria de Salud de Mexico","year":"2012","unstructured":"Secretaria de Salud de Mexico. Diagn\u00f3stico y Tratamiento del C\u00e1ncer de Mama en Segundo y Tercer Nivel de Atenci\u00f3n; 2012. p. 1\u2013102."},{"key":"4833_CR8","doi-asserted-by":"publisher","first-page":"3658","DOI":"10.1002\/cncr.25961","volume":"117","author":"F Lara-Medina","year":"2011","unstructured":"Lara-Medina F, Perez-Sanchez V, Saavedra-Perez D, Blake-Cerda M, Arce C, Motola-Kuba D, et al. Triple-negative breast cancer in Hispanic patients: high prevalence, poor prognosis, and association with menopausal status, body mass index, and parity. Cancer. 2011;117:3658\u201369.","journal-title":"Cancer"},{"key":"4833_CR9","first-page":"482","volume-title":"C\u00e1ncer de mama en mujeres mexicanas menores de 40 a\u00f1os","author":"J Robles-Castillo","year":"2011","unstructured":"Robles-Castillo J, Ruvalcaba-Lim\u00f3n E. Ginecologia y Obstetricia de Mexico. In: C\u00e1ncer de mama en mujeres mexicanas menores de 40 a\u00f1os, vol. 79; 2011. p. 482\u20138."},{"key":"4833_CR10","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1002\/cncr.29058","volume":"121","author":"C Villarreal-Garza","year":"2015","unstructured":"Villarreal-Garza C, Alvarez-Gomez RM, Perez-Plasencia C, Herrera LA, Herzog J, Castillo D, et al. Significant clinical impact of recurrent BRCA1 and BRCA2 mutations in Mexico. Cancer. 2015;121:372\u20138.","journal-title":"Cancer"},{"key":"4833_CR11","doi-asserted-by":"crossref","unstructured":"Mohar-Betancourt A, Reynoso-Noveron N, Armas-Texta D, Gutierrez-Delgado C, Torres-Dominguez JA. Cancer trends in Mexico: essential data for the creation and follow-up of public policies. J Glob Oncol 2017;JGO.2016.007476\u20139.","DOI":"10.1200\/JGO.2016.007476"},{"key":"4833_CR12","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1136\/jclinpath-2013-201819","volume":"67","author":"AM Shaaban","year":"2014","unstructured":"Shaaban AM, Purdie CA, Bartlett JMS, Stein RC, Lane S, Francis A, et al. HER2 testing for breast carcinoma: recommendations for rapid diagnostic pathways in clinical practice. J Clin Pathol; BMJ Publishing Group. 2014;67:161\u20137.","journal-title":"J Clin Pathol"},{"key":"4833_CR13","doi-asserted-by":"crossref","unstructured":"Anderson BO, Yip C-H, Smith RA, Shyyan R, Sener SF, Eniu A, et al. Guideline implementation for breast healthcare in low-income and middle-income countries: overview of the breast health global initiative global summit 2007. Cancer Wiley Subscription Services, Inc., A Wiley Company; 2008. pp. 2221\u20132243.","DOI":"10.1002\/cncr.23844"},{"key":"4833_CR14","doi-asserted-by":"publisher","first-page":"961","DOI":"10.6004\/jnccn.2016.0103","volume":"14","author":"RW Carlson","year":"2016","unstructured":"Carlson RW, Scavone JL, Koh W-J, McClure JS, Greer BE, Kumar R, et al. NCCN framework for resource stratification: a framework for providing and improving global quality oncology care. J Natl Compr Cancer Netw. 2016;14:961\u20139.","journal-title":"J Natl Compr Cancer Netw"},{"key":"4833_CR15","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1200\/JOP.2016.014290","volume":"12","author":"LT Chuang","year":"2016","unstructured":"Chuang LT, Temin S, Berek JS. Management and Care of Women with Invasive Cervical Cancer: American Society of Clinical Oncology resource-stratified clinical practice guideline summary. J Oncol Pract. 2016;12:693\u20136.","journal-title":"J Oncol Pract"},{"key":"4833_CR16","unstructured":"World Health Organization. Executive summary. National Cancer Control Programmes. Policies and Managerial Guidelines. 2012:1\u201324."},{"key":"4833_CR17","volume-title":"Encuesta Intercensal 2015","author":"Instituto Nacional de Estad\u00edstica y Geograf\u00eda","year":"2015","unstructured":"Instituto Nacional de Estad\u00edstica y Geograf\u00eda. [Encuesta Intercensal 2015]. 2015."},{"key":"4833_CR18","first-page":"1","volume-title":"Indice de Competitividad Estatal 2016","author":"Instituto Mexicano para la Competitividad","year":"2016","unstructured":"Instituto Mexicano para la Competitividad. Indice de Competitividad Estatal 2016; 2016. p. 1\u2013202."},{"key":"4833_CR19","first-page":"432","volume":"147","author":"JP Solomon","year":"2017","unstructured":"Solomon JP, Dell'Aquila M, Fadare O, Hasteh F. Her2\/neu status determination in breast Cancer. A Single Institutional Experience Using a Dual-Testing Approach With Immunohistochemistry and Fluorescence In Situ Hybridization Am J Clin Pathol. 2017;147:432\u20137.","journal-title":"A Single Institutional Experience Using a Dual-Testing Approach With Immunohistochemistry and Fluorescence In Situ Hybridization Am J Clin Pathol"},{"key":"4833_CR20","doi-asserted-by":"publisher","first-page":"140","DOI":"10.5858\/arpa.2015-0108-OA","volume":"140","author":"TH Lim","year":"2016","unstructured":"Lim TH, Lim AST, Thike AA, Tien SL, Tan PH. Implications of the updated 2013 American Society of Clinical Oncology\/College of American Pathologists Guideline Recommendations on human epidermal growth factor receptor 2 gene testing using immunohistochemistry and fluorescence in situ hybridization for breast Cancer. Arch Pathol Lab Med. 2016;140:140\u20137.","journal-title":"Arch Pathol Lab Med"},{"key":"4833_CR21","first-page":"1","volume-title":"[Cuadro Basico de Medicamentos. Oncologia] Instituto Mexicano del Seguro Social","author":"Instituto Mexicano del Seguro Social","year":"2017","unstructured":"Instituto Mexicano del Seguro Social. [Cuadro Basico de Medicamentos. Oncologia] Instituto Mexicano del Seguro Social; 2017. p. 1\u201348."},{"key":"4833_CR22","first-page":"951","volume":"122","author":"DA Novis","year":"1998","unstructured":"Novis DA, Zarbo RJ, Saladino AJ. Interinstitutional comparison of surgical biopsy diagnosis turnaround time: a College of American Pathologists Q-probes study of 5384 surgical biopsies in 157 small hospitals. Arch Pathol Lab Med. 1998;122:951\u20136.","journal-title":"Arch Pathol Lab Med"},{"key":"4833_CR23","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","volume":"31","author":"AC Wolff","year":"2013","unstructured":"Wolff AC, Hammond MEH, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast Cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline Update. J Clin Oncol. 2013;31:3997\u20134013.","journal-title":"J Clin Oncol"},{"issue":"6","key":"4833_CR24","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.pathol.2016.05.007","volume":"48","author":"Adrienne L. Morey","year":"2016","unstructured":"Morey AL, Brown B, Farshid G, Fox SB, Francis GD, McCue G, et al. Determining HER2 (ERBB2) amplification status in women with breast cancer: final results from the Australian in situ hybridisation program. Pathology Elsevier; 2016;48:535\u2013542.","journal-title":"Pathology"},{"issue":"1","key":"4833_CR25","doi-asserted-by":"publisher","first-page":"u209223.w3773","DOI":"10.1136\/bmjquality.u209223.w3773","volume":"4","author":"Saeed Alshieban","year":"2015","unstructured":"Alshieban S, Al-Surimi K. Reducing turnaround time of surgical pathology reports in pathology and laboratory medicine departments. BMJ Qual Improv Rep BMJ Open Quality; 2015;4:u209223.w3773.","journal-title":"BMJ Quality Improvement Reports"},{"key":"4833_CR26","doi-asserted-by":"crossref","unstructured":"Boleij A, Tembuyser L, Taylor A, Kafatos G, Jenkins-Anderson S, Tack V, et al. PD-015A survey on current RAS-mutation testing practices in Europe. Ann Oncol Oxford University Press. 2015;26:iv105\u20135.","DOI":"10.1093\/annonc\/mdv234.14"},{"key":"4833_CR27","first-page":"1","volume-title":"Key Performance Indicators in Pathology","author":"Pathologists TRCO","year":"2013","unstructured":"Pathologists TRCO. Key Performance Indicators in Pathology; 2013. p. 1\u201323."},{"key":"4833_CR28","first-page":"1","volume-title":"Manual Metodol\u00f3gico de Indicadores M\u00e9dicos 2016","author":"Instituto Mexicano del Seguro Social","year":"2016","unstructured":"Instituto Mexicano del Seguro Social. Manual Metodol\u00f3gico de Indicadores M\u00e9dicos 2016; 2016. p. 1\u2013452."}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-4833-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-018-4833-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-4833-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T17:18:44Z","timestamp":1662139124000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-018-4833-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,27]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["4833"],"URL":"https:\/\/doi.org\/10.1186\/s12885-018-4833-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/198721","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,27]]},"assertion":[{"value":"25 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This research was reviewed and approved by the Mexican Institute of Social Security (IMSS)\u2018s National Scientific Research Committee and its National Bioethics Committee, under protocol number R-2017-785-010, and locally by IMSS\u2019 Local Research and Ethics Committee, under specific protocol number R-2017-1602-14 HGR1 Charo, Michoacan. Stanford\u2019s Institutional Review Board provided a non-human subject determination under eProtocol: 40704. Researchers only received access to non-identifiable data under the considerations of the applicable Mexican bylaws on health research, patient privacy, and electronic medical records. Consent was not required.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"RAR declares to be IMSS\u2019s state delegate in Michoacan, overseeing the hospital mentioned in this study. The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"933"}}